Downregulation of Mitochondrial Fusion Protein Expression Affords Protection from Canonical Necroptosis in H9c2

Yuki Toda1, Sang-Bing Ong2,3,4,5, Toshiyuki Yano1

  • 1Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan.

Insights

Inhibition of mitochondrial fusion attenuated necroptosis by increasing TGFβ-activated kinase (TAK1) expression, suppressing RIP1 activity in H9c2 cardiomyoblasts. This reveals a novel mechanism linking mitochondrial dynamics to cell death in cardiovascular disease.

Area of Science:

  • Cardiovascular Biology
  • Cell Death Mechanisms
  • Mitochondrial Biology

Background:

  • Necroptosis and altered mitochondrial dynamics are implicated in cardiovascular diseases.
  • Mitochondrial morphology plays a role in cell death pathways.
  • Understanding these links is crucial for developing new therapeutic strategies.

Purpose of the Study:

  • To investigate the role of mitochondrial morphology in TNF/zVAD-induced necroptosis.
  • To determine the impact of mitochondrial fission and fusion proteins on necroptosis.
  • To elucidate the signaling pathways connecting mitochondrial dynamics and necroptosis.

Main Methods:

  • Time-course analysis of mitochondrial morphology in H9c2 cells treated with TNF/zVAD.
  • Gene knockdown of mitochondrial dynamics proteins (Drp1, Fis1, Mfn1/2, Opa1).
  • Pharmacological inhibition of Drp1 (Mdivi-1) and TAK1.
  • Assessment of necroptosis, RIP1 activity, and TAK1 expression.

Main Results:

  • TNF/zVAD treatment initially shortened mitochondria, followed by elongation.
  • Inhibition of mitochondrial fusion (Mfn1/2, Opa1 knockdown) attenuated necroptosis.
  • Mitochondrial fusion inhibition upregulated TAK1 expression and reduced RIP1 activity.
  • Fission inhibition (Drp1, Fis1 knockdown, Mdivi-1) had no effect on necroptosis.

Conclusions:

  • Mitochondrial fusion inhibition attenuates canonical necroptosis.
  • This attenuation is mediated by increased TAK1 expression, which suppresses RIP1 activity.
  • Targeting mitochondrial fusion offers a potential therapeutic approach for cardiovascular diseases involving necroptosis.